SureTrader Advertisement SureTrader
Home > Boards > Free Zone > Health and Sciences > Biotech Values

If the progression assessments for the two metrics

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 618
Posts 92,306
Boards Moderated 28
Alias Born 09/05/02
160x600 placeholder
Wall Street Not Rewarding Low-expectation Earnings Beats
Health-care, media, energy earnings start winding season down Earnings beats this season have been cheapened, with lower-than-usual...
Top Equities Stories Of The Day
FCC to Sell Maximum Amount in TV Airwave Auction
Fitbit Scores Against Jawbone in Patent Dispute
Valeant Default Fears 'Cured' -- WSJ
Exxon Swoons, but Investors Cheer -- WSJ
CBOE Reports Higher Earnings, Revenue Thanks to Trading Shift
Amazon Kindle Oasis Video Review: Up Close With the Luxury E-Reader
Drugmakers Place Big Bets on Cancer Medicines
Abbott to Acquire St. Jude -- WSJ
DewDiligence Member Level  Thursday, 05/24/12 02:22:04 PM
Re: jq1234 post# 142539
Post # of 201066 
If the progression assessments for the two metrics are made on the same schedule for every patient, it shouldn’t be possible for PFS to be greater than TTP. A death in between progression assessments ought not to cause a patient to be deleted from the TTP dataset, but rather for TTP to be censored at the time of death.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist